New assay bringsvalidated HRD technology from Myriad Geneticsto the Illumina TruSight Oncology 500, a single, comprehensive pan-cancer test to identify key variants critical for cancer development and progression SAN DIEGO, June 23, 2022 /PRNewswire/ Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of a research test, codeveloped with Merck (known as MSD outside the United States and Canada). The research test builds upon Illumina's commitment to broadly enable comprehensive genomic profiling and enhance research critical to realizing precision medicine in oncology. The test adds assessment of a new genomic signature to the distributed, market leading TruSight Oncology 500 assay. It will be available globally, excluding the United States and Japan and will enable researchers to unlock deeper insights about the tumor genome by identifying genetic mutations used in the evaluation of homologous recombination de
New assay brings validated HRD technology from Myriad Genetics to the Illumina TruSight Oncology 500, a single, comprehensive pan-cancer test to identify key variants critical for cancer development
/PRNewswire/ Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced Joydeep Goswami, Chief Strategy.
/PRNewswire/ Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the first quarter of fiscal year 2022, which include consolidated.
/PRNewswire/ Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: BofA Securities 2022.